1. Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev 2023; 28: 585-96.
2.
Yan T, Zhu S, Yin X, et al. Burden, Trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 Study. J Am Heart Assoc 2023; 12: e027852.
3.
Yang C, Jia Y, Zhang C, et al. Global, regional, and national burdens of heart failure in adolescents and young adults aged 10–24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021. eClinicalMedicine 2025; 79: 102998.
4.
Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85: 1093-129.
5.
Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med 2017; 19: 23.
6.
Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
7.
Shiba T, Ishii S, Okamura T, et al. Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: a sub-analysis by body mass index and age of pooled data from three clinical trials. Diabetes Res Clin Pract 2017; 131: 169-78.
8.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
9.
Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137: 119-29.
10.
Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 2021; 143: 516-25.
11.
Omar M, Jensen J, Ali M, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol 2021; 6: 836-40.
12.
Afshani MR, Torfi E, Akiash N, et al. Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction. Acta Cardiol 2024; 79: 419-25.
13.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2021; 77: 243-55.
14.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
15.
Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
16.
Yan Q, Chen X, Yu C, Yin Y. Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2024; 24: 663.
17.
Pan D, Xu L, Chen P, et al. Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med 2021; 8: 683281.
18.
Mouffokes A, Soliman Y, Amer BE, et al. The effect of empagliflozin on echocardiographic parameters in diabetic patients after acute myocardial infarction: a systematic review and meta-analysis with trial sequential analysis. Ir J Med Sci 2024; 193: 2223-38.
19.
Fan G, Guo DL. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials. Eur J Intern Med 2023; 114: 49-57.
20.
Ciampi Q, Villari B. Role of echocardiography in diagnosis and risk stratification in heart failure with left ventricular systolic dysfunction. Cardiovasc Ultrasound 2007; 5: 34.
21.
Shah AM, Claggett B, Sweitzer NK, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation Heart Fail 2014; 7: 104-15.
22.
Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2019; 74: 2858-73.
23.
Gentile F, Sciarrone P, Panichella G, et al. Echocardiography-derived forward left ventricular output improves risk prediction in systolic heart failure. J Am Soc Echocardiogr 2024; 37: 937-46.
24.
Azevedo PS, Minicucci MF, Santos PP, et al. Energy metabolism in cardiac remodeling and heart failure. Cardiol Rev 2013; 21: 135-40.
25.
Bekfani T, Elsaied MB, Derlien S, et al. Skeletal muscle function, structure, and metabolism in patients with heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Circ Heart Fail 2020; 13: e007198.
26.
He Y, Huang W, Zhang C, et al. Energy metabolism disorders and potential therapeutic drugs in heart failure. Acta Pharm Sin B 2021; 11: 1098-116.
27.
Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol 2021; 20: 32.
28.
Gaborit B, Ancel P, Abdullah AE, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol 2021; 20: 57.
29.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 2019; 73: 1931-44.
30.
Makrecka-Kuka M, Korzh S, Videja M, et al. Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. Cardiovasc Drugs Ther 2020; 34: 791-7.
31.
Choi J, Matoba N, Setoyama D, et al. The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Commun Biol 2023; 6: 278.
32.
Schauer A, Adams V, Kammerer S, et al. Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain. Circ Heart Fail 2024; 17: e011107.
33.
Cai W, Chong K, Huang Y, et al. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol 2024; 69: 103010.
